Skyrizi® Intravenous (risankizumab-rzaa)

Coverage: Skyrizi IV (risankizumab-rzaa) is covered only as induction therapy for adults (≥18) with moderately-to-severely active Crohn’s disease; pediatric, maintenance, or non‑induction dosing schedules are excluded. Key requirements: prescriber must be a gastroenterologist or consult, dosing must be 600 mg IV at Weeks 0, 4, and 8, documentation of at least one qualifying condition (ileocolonic resection, enterocutaneous/rectovaginal fistulas, prior trial of one systemic therapy, current/prior systemic corticosteroid use, or corticosteroid contraindication), applicable safety documentation, and initial approval is limited to 3 months.

"Documentation of diagnosis: moderately to severely active Crohn's disease in an adult."

Sign up to see full coverage criteria, indications, and limitations.